QIAGEN NV QGEN
NYSE · United States · Health Technology
$43.20-0.56 (-1.28%)
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
The global biomarkers market is projected to grow from USD 67.95 billion in 2026 to USD 112.10 billion by 2031, registering a 10.5% CAGR. Growth is driven by precision medicine, companion diagnostics, AI, bioinformatics, digital pathology and multi-omics technologies. Predictive biomarkers led the efficacy segment in 2025, while immunoassays held the largest technology share. Asia Pacific is forecast to be the fastest-growing region. Key players include Roche, Abbott, Thermo Fisher Scientific, Q
Qiagen (NYSE:QGEN) just received U.S. FDA clearance for its QIAstat-Dx gram-negative bloodstream infection panel, giving American laboratories full access to the company’s rapid sepsis testing portfolio in a single automated system. Qiagen’s latest FDA clearance lands after a period of mixed trading, with the share price up 15.1% over the past 90 days but still down 5.4% year to date, while the 1-year total shareholder return of 3.2% points to modest longer term gains. Scan how Qiagen’s...
Earlier this week, QIAGEN announced that U.S. labs now have access to its full QIAstat-Dx bloodstream infection portfolio after FDA clearance of a one-hour gram-negative bacteria and antibiotic resistance panel, complementing an existing gram-positive and fungal panel and expanding its syndromic infectious disease testing menu. This clearance materially broadens QIAGEN’s coverage to 33 bloodstream pathogen targets and 28 resistance markers, reinforcing the clinical relevance of its automated...
Demand is rising in diagnostics, precision medicine and biopharma research, while nanotechnology, automation and AI unlock targeted therapies and high-throughput workflows.Dublin, Sept. 28, 2026 (GLOBE NEWSWIRE) -- "Magnetic Beads - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global magnetic beads market was valued at an estimated US$3.3 billion in 2025 and is projected to reach US$7.4 billion by 2032, advancing at a compound annual growth rate (CAG
GERMANTOWN, Md. & VENLO, Netherlands, September 28, 2026--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that U.S. laboratories now have access to the complete QIAstat-Dx bloodstream infection portfolio following clearance of a new panel by the U.S. Food and Drug Administration (FDA).
VENLO, Netherlands & GERMANTOWN, Md., September 24, 2026--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of QIAmini, a compact automated sample preparation system designed to give research laboratories a time-saving and cost-efficient alternative to processing samples by hand.
VENLO, Netherlands, September 18, 2026--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it will hold an Extraordinary General Meeting of Shareholders on November 6, 2026, at 2:00 p.m. CET.
AI, Advanced Sequencing and Precision Medicine Drive Genomics Opportunities Across Diagnostics, Drug Development and Preventive CareDublin, Sept. 18, 2026 (GLOBE NEWSWIRE) -- "Genomics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035" has been added to ResearchAndMarkets.com's offering. Global Genomics Market Forecast to Reach USD 188.7 Billion by 2035, Driven by Precision Healthcare and Sequencing Innovation The global genomics market was valued at USD 44.7 bi
Pharmacogenomics Expands as Multi-Gene Testing, Bioinformatics and Precision Diagnostics Drive Clinical AdoptionDublin, Sept. 18, 2026 (GLOBE NEWSWIRE) -- "Pharmacogenomics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035" has been added to ResearchAndMarkets.com's offering. Global Pharmacogenomics Market to Reach USD 15.4 Billion by 2035, Driven by Precision Medicine Adoption The global pharmacogenomics market was valued at USD 5.7 billion in 2025 and is proje
Qiagen (NYSE:QGEN) shares gained 4% on Thursday morning following a media report that several private equity firms are considering potential offers for the molecular testing company. German publication Manager Magazin reported that TPG and Bain Capital are among the firms weighing bids for Qiagen, although it did not identify sources for the information.
On August 27, QIAGEN N.V. (NYSE:QGEN) launched QIAsymphony Connect, a new automated platform for clinical nucleic acid extraction aimed at laboratories running liquid biopsy, oncology, and infectious disease tests. The timing is notable. On August 5, QIAGEN had already posted second-quarter results that beat its own guidance, with growth pillars like Sample technologies and QIAcuity […]
The global transcriptome sequencing market is projected to reach $11.8 billion by 2035, growing at a 7.3% CAGR from 2025 to 2035. Growth is driven by falling sequencing costs, precision medicine, drug discovery, biomarker development, single-cell and spatial transcriptomics, long-read RNA sequencing, and AI-powered analytics. Consumables, bulk RNA-seq, drug discovery applications, and pharmaceutical and biotechnology companies led the market in 2025. North America held the largest regional share
A gene sequencing leader is on a powerful run fueled by real business quality, forcing investors to decide if the engine has more power than the price tag already reflects.
Qiagen (QGEN) has drawn fresh attention after Q2 2026 adjusted earnings and net sales came in above consensus, even as estimates had recently drifted lower, and management reaffirmed its full year outlook. The Q2 beat and reaffirmed guidance contrast with a mixed share price backdrop for Qiagen, with the stock closing at US$43.47 after a daily share price return that slipped 0.89% but a 90 day share price return of 18.51% pointing to improving momentum. Capitalize on Qiagen's earnings...
In late August 2026, Qiagen launched QIAsymphony Connect, an IVD-compliant automated nucleic acid extraction platform with FDA and EUDAMED listings, while also announcing a CEO transition to Jon Pratt from September 1 and reporting Q2 2026 results that exceeded analyst expectations with reaffirmed guidance. The combination of a next-generation automation platform, leadership change and better-than-expected quarterly performance highlights how Qiagen is tightening its focus on high-throughput...
The global multiplex assays market is projected to grow from US$6.8 billion in 2025 to US$12.4 billion by 2030, at a 12.8% CAGR. North America leads with a 34% share, while Asia Pacific is the fastest-growing region at 15.5%; India is forecast to expand at 16.9%. Consumables account for 68% of sales and protein multiplex assays hold 42%. Growth is driven by precision medicine, companion diagnostics, biomarker R&D, molecular diagnostics and laboratory automation. Key players include Thermo Fisher
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.